Hello guys, Welcome to Africa's Largest Video Search Engine, and you are watching Targeting Cancer Pathways: Understanding Immune Checkpoints. and this video is uploaded by Cell Signaling Technology, Inc. at 2020-04-29T07:00:34-07:00. We are just promoting this video only for entertainment and educational purpose only. I hop you like our Video Search Engine. [zhnAvTxhZB0]
| Name | Targeting Cancer Pathways: Understanding Immune Checkpoints |
| Video Uploader | Video From Cell Signaling Technology, Inc. |
| Upload Date | This Video Uploaded At 29-04-2020 14:00:34 |
| Video Discription | Participating Experts: James Allison, PhD, (MD Anderson), Gordon J. Freeman, PhD, (Dana-Farber), and Philip J. Gotwals, PhD) (Novartis) ⬇️ Expand “Show More” to view abstract and table of contents Explore/download the signaling pathway diagram for Immune Checkpoint Signaling in the Tumor Microenvironment https://cst-science.com/2q5jtr Tumors manipulate their microenvironment in order to evade surveillance and elimination by the immune system. To do this, cancer cells can co-opt inhibitory ligands and their receptors that regulate T cell effector function. Intervention targeting these pathways, known as immune checkpoint therapies, have been the subject of intense translational research and clinical development. This webinar explores how tumors exploit immune modulatory mechanisms to generate and thrive in their own immunosuppressive microenvironment, and how these mechanisms can be targeted to develop better therapeutic options. Topics covered include: • A historical overview of immune checkpoint research and examination of the effect of mutational load on clinical response. • How PD-1 immunotherapy stops certain cancers from turning off the anticancer immune response. • Discuss general therapeutic approaches to activating the immune system to treat cancer. Table of Contents 0:00 Welcome and overview 2:46 James Allison speaker profile 3:35 Immune checkpoint blockade in cancer therapy: New inishgts, opportunities, and prospects for cures 4:18 FDA approval of antibodies targeting immune chckpoints 6:10 Dynamic integration of TCR and costimulatory signals 7:49 CTLA-4 blockade enhances tumor-specific immune responses 9:04 Anti-CTLA-4 induces regression of transplantable colon carcinoma 10:29 Anti-CTLA-4/GVAX therapy activates the tumor vasculature and increases infiltration of tumors by CD4 and CD8 effector cells 12:10 The longest survivor on ipilimumab? 13:12 Ipilimumab in metastatic melanoma: pooled OS analysis including EAP data 14:16 Anti-CTLA-4, Anti-PD-1 comparison 15:13 Clinical activity: Ipilimumba and Nivolumab combination therapy 16:05 Mutational load varies in human cancers 17:12 Potential characteristics of immunogenic and nonimmunogenic tumors 17:21 Infiltrates in prostate cancer pre and post anti-CTLA4 therapy 18:09 Improving survival with immunotherapy 18:55 Gordon Freeman speaker profile 19:34 Immunology has offered hope for 100 years 20:43 T cells need antigen recognition + co-stimulatory signals; PD-1 pathway inhibits T cell activation 23:34 PD-1 or PD-L1 blockade allows reactivation of anti-tumor T cell responses 24:29 Phase I clinical trial of nivolumab – kidney cancer cohort 25:45 PD-1 cancer immunotherapy tolerance, safety, adverse events 27:25 PD-1 is better than chemotherapy for melanoma; overall response rates 28:39 The immune system recognizes protein coding changes in the tumor cell called neoantigens 30:04 Durable responses to immunotherapy compared to Braf tyrosine kinase inhibition 32:32 Understanding immunology and genetics has identified groups that respond well to PD-1 and PD-L1 therapy 33:40 Exhausted tumor infiltrating lymphocytes express multiple immunoinhibitory receptors 35:47 Future directions 38:08 Philip Gotwals speaker profile 38:53 Therapeutic targeting of the immune system to treat cancer 40:45 Targeted and immune-modulatory therapeutics are being combined in melanoma 43:55 A wealth of important targets for T cell modulation 44:37 LAG-3 as a target for therapeutic approaches 46:06 Chimeric Antigen Receptor (CAR-T) engineering 47:22 CTL019 therapy: overview of recent clinical data in hematologic malignancies 48:47 Targeting the immunosuppressive tumor microenvironment: IDO 50:50 Talimogene (T-VEC) study 51:29 Local delivery may lead to systemic therapy: The abscopal effect 52:28 STING agonist for enhancing immune reponse to tumors 53:44 Towards complete, durable remission for cancer patients 54:32 Question and Answer About CST®: Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high-quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan. https://cellsignal.com/about All trademarks are the property of their respective owners. For the most up-to-date trademark information, please visit https://www.cellsignal.com/trademarks #Antibody #CSTWebinar #immunotherap [zhnAvTxhZB0] |
| Category | Science & Technology |
| Tags | Antibody | immunotherapy | webinar | James Allison | Gordon Freeman | Philip Gotwals | immune checkpoint | checkpoint therapy | PD-1 | PD-L1 | PD-L2 | CTLA-4 | co-stimulation | co-inhibition | T cell | CD28 | B7 | CD4 | CD8 | ipilimumab | nivolumab | pembrolizumab | neoantigen | OX40 | CAR-T | T cell exhaustion | research reproducibility | validation | yt:cc=on |
